Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › PEX168 monotherapy phase 3a

PEX168 monotherapy phase 3a

PEG-loxenatide · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
PEG-loxenatide
Population
t2d
Phase
3
Participants
361
Duration
24 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
100 μgt2d china24361——−1.0 vs −0.21.6 vs 0.8—5.6 vs 0.02.4 vs 0.0——press release
200 μgt2d china24361——−1.3 vs −0.22.5 vs 0.8—10.0 vs 0.08.3 vs 0.0——press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (8)
  • 100 μg · hba1c · publication
    The HbA1c least-square mean (95% CI) change from baseline to week 24 was greater for PEX168/100 μg (-1.02% [-1.21%, -0.83%]) and PEX168/200 μg (-1.34% [-1.54%, -1.15%]) than for placebo (-0.17% [-0.36%, 0.02%])
  • 100 μg · nausea · publication
    nausea (5.6%, 10.0% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
  • 100 μg · vomiting · publication
    vomiting (2.4%, 8.3% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
  • 100 μg · ae_dc · publication
    (PEX168/100 μg: N = 2 [1.6%], PEX168/200 μg: N = 3 [2.5%] and placebo: N = 1 [0.8%]) discontinued treatment because of AEs
  • 200 μg · hba1c · publication
    The HbA1c least-square mean (95% CI) change from baseline to week 24 was greater for PEX168/100 μg (-1.02% [-1.21%, -0.83%]) and PEX168/200 μg (-1.34% [-1.54%, -1.15%]) than for placebo (-0.17% [-0.36%, 0.02%])
  • 200 μg · nausea · publication
    nausea (5.6%, 10.0% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
  • 200 μg · vomiting · publication
    vomiting (2.4%, 8.3% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
  • 200 μg · ae_dc · publication
    (PEX168/100 μg: N = 2 [1.6%], PEX168/200 μg: N = 3 [2.5%] and placebo: N = 1 [0.8%]) discontinued treatment because of AEs

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: PEX168 monotherapy phase 3a. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/pex168-monotherapy-phase-3a/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.